Verrica Pharmaceuticals Inc. Investors: Class Action Lawsuit…

Verrica Pharmaceuticals Inc. Investors: Class Action Lawsuit…


investors with losses of $100,000 Contact the law firm for free to learn more about recovering their losses

LOS ANGELES, July 31, 2022 (GLOBE NEWSWIRE) — The law firm of Portnoy advises Verrica Pharmaceuticals Inc. VRCA Investors that a class action lawsuit has been filed on behalf of investors. Verrica investors who have lost money investing are encouraged to do so Contact Lesley Portnoy, Esq.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: lesley@portnoylaw.comto discuss your legal rights, or click here to join the case about Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

Verrica is a dermatology therapeutics company developing medicines for skin conditions that require medical treatment. Verrica’s lead product candidate, VP-102, is a drug combination of cantharidin, Verrica’s topical solution, delivered via a single-use, precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum.

In December 2020, Verrica submitted its New Drug Application (“NDA”) to the United States Food and Drug Administration (“FDA”) seeking regulatory approval of VP-102 for the treatment of molluscum.

On September 20, 2021, after market close, Verrica announced receipt of a Complete Response Letter (“CRL”) regarding deficiencies in a facility of Verrica’s contract manufacturer related to the Company’s NDA. As a result of this news, the Company’s stock price fell $1.00 per share, or approximately 8.31%, from $12.03 per share to a closing price of $11.03 per share on September 21, 2021.

In November 2021, Verrica resubmitted the NDA for VP-102, claiming, “[t]The re-submission concerns the successful elimination of “inspection deficiencies” in the production facility.

On May 24, 2022, after market close, Verrica announced receipt of another Complete Response Letter regarding the VP-102 NDA, stating that it…

Source story

More to explorer